Overview

Efficacy Vulvovaginitis Candida

Status:
Terminated

Trial end date:
2004-10-01

Target enrollment:

Participant gender:

Summary

To compare the therapeutic efficacy of 10 mg, 40 mg, 80 mg, 160 mg and 320 mg of albaconazole, as a single oral dose, in women affected by acute non-complicated vulvovaginitis due to Candida spp.

Phase:

Phase 2

Details

Lead Sponsor:

J. Uriach and Company

Treatments:

Albaconazole